Abstract
Peroxisomal proliferator activated receptor γ(PPARγ) belongs to the family of nuclear hormone receptors (NHRs), which directly regulate transcription of target genes. The regulatory role of this receptor on lipid metabolism and insulin sensitization is well established. Recently, the overexpression of this receptor in many human cancers has been identified and understanding its biological significance forms the current theme. PPARγ activation by specific agonists leads to growth inhibition, apoptosis and differentiation of tumor cells. PPARγ possess evident tumor promoting properties but the receptor independent effects of its ligands compound the understanding of its biology in cancers. This review highlights the multifaceted role of PPARγ in cancer progression with specific reference to colon, breast, gastric, lung and urological cancers. Molecular events as well as the mediators involved are analyzed in detail along with PPARγ independent effects of ligands under each cancer type. The crucial cross talk that exists between Wnt and PPARγ signaling is also summarized. An attempt has been made to identify the existing lacunae in understanding the biology of PPARγ in cancers along with suggestions for possible rectification.
Keywords: PPAR, receptor, Wnt, breast cancer, colon cancer, gastric cancer, lung cancer, urological cancer
Current Molecular Medicine
Title: Biology of PPARγ in Cancer: A Critical Review on Existing Lacunae
Volume: 7 Issue: 6
Author(s): Anand Krishnan, S. Asha Nair and M. Radhakrishna Pillai
Affiliation:
Keywords: PPAR, receptor, Wnt, breast cancer, colon cancer, gastric cancer, lung cancer, urological cancer
Abstract: Peroxisomal proliferator activated receptor γ(PPARγ) belongs to the family of nuclear hormone receptors (NHRs), which directly regulate transcription of target genes. The regulatory role of this receptor on lipid metabolism and insulin sensitization is well established. Recently, the overexpression of this receptor in many human cancers has been identified and understanding its biological significance forms the current theme. PPARγ activation by specific agonists leads to growth inhibition, apoptosis and differentiation of tumor cells. PPARγ possess evident tumor promoting properties but the receptor independent effects of its ligands compound the understanding of its biology in cancers. This review highlights the multifaceted role of PPARγ in cancer progression with specific reference to colon, breast, gastric, lung and urological cancers. Molecular events as well as the mediators involved are analyzed in detail along with PPARγ independent effects of ligands under each cancer type. The crucial cross talk that exists between Wnt and PPARγ signaling is also summarized. An attempt has been made to identify the existing lacunae in understanding the biology of PPARγ in cancers along with suggestions for possible rectification.
Export Options
About this article
Cite this article as:
Krishnan Anand, Nair Asha S. and Pillai Radhakrishna M., Biology of PPARγ in Cancer: A Critical Review on Existing Lacunae, Current Molecular Medicine 2007; 7 (6) . https://dx.doi.org/10.2174/156652407781695765
DOI https://dx.doi.org/10.2174/156652407781695765 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
β-Cyclodextrin Complexes of Hydrolyzable Adamantanoyl-IUdR Prodrugs - Radioiodination and Biodistribution in Mice Bearing Implanted KBALB Tumours
Current Radiopharmaceuticals Chemoprevention of Colorectal Carcinogenesis by Natural Anti-Inflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Potential Novel Treatments for Bipolar Depression: Ketamine, Fatty Acids, Anti-inflammatory Agents, and Probiotics
CNS & Neurological Disorders - Drug Targets Inorganic Nanoparticles for Enhanced Photodynamic Cancer Therapy
Current Drug Discovery Technologies The Application of Stimuli-responsive Nanocarriers for Targeted Drug Delivery
Current Topics in Medicinal Chemistry Current Biomarkers for Lung Cancer
Current Signal Transduction Therapy Identification of Phosphoproteins and their Impact as Biomarkers in Cancer Therapeutics
Current Signal Transduction Therapy Peroxisome Proliferator Activated Receptor-Gamma Ligands as Potent Antineoplastic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Biodistribution and Pharmacokinetics of I-131 Labelled 4- Iodophenylacetic Acid
Current Radiopharmaceuticals A Novel Marine Drug, SZ–685C, Induces Apoptosis of MMQ Pituitary Tumor Cells by Downregulating miR–200c
Current Medicinal Chemistry Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery
Current Medicinal Chemistry Adenovirus-Based Cancer Gene Therapy
Current Gene Therapy Modulation of the TRPV1 Channel: Current Clinical Trials and Recent Patents with Focus on Neurological Conditions
Recent Patents on CNS Drug Discovery (Discontinued) Aurora B: A New Prognostic Marker and Therapeutic Target in Cancer
Current Medicinal Chemistry Mechanisms of Allostery and Membrane Attachment in Ras GTPases: Implications for Anti-Cancer Drug Discovery
Current Medicinal Chemistry Human Carcinogenesis and Bracken Fern: A Review of the Evidence
Current Medicinal Chemistry HGF and RhoGTPases in Cancer Cell Motility
Current Signal Transduction Therapy New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer
Current Drug Targets The Potential for Targeting Oncogenic WNT/β -Catenin Signaling in Therapy
Current Drug Targets Electrochemical Biosensors as a Screening Tool of In Vitro DNA-Drug Interaction
Current Pharmaceutical Analysis